Because of the improved bioavailability, specificity, and signal-to-noise ratio of 18F-DPA-714 compared with other TSPO tracers, 18F-DPA-714 was used in target validation studies on preclinical and clinical stroke and to track the response to immunomodulatory treatment (20). Here, TSPO is linked to stroke disorder.